PLX51107

Plexxikon MOA PLX51107

Targeted Indication Status Sites link to clinicaltrials.gov

Solid Tumors
Hematologic
Malignancies

Phase 1b

San Antonio, TX
Charleston, SC
Columbus, OH
Pittsburgh, PA
Baltimore, MD
Detroit, MI
New York, NY

NCT02683395

These compounds and/or uses are investigational and have not been approved by the FDA or any other regulatory authority for the uses under investigation. Image above depicts proposed targeted pathway of the investigational agent(s) in the targeted indication.

Settleman J. Nature. 2016; 529; 289-290.
Data on file.